Strategic Merger to Build Global MSK Imaging AI Provider
Medimaps Group and Radiobotics have entered into a strategic merger agreement to combine their artificial intelligence (AI) capabilities in musculoskeletal (MSK) medical imaging. The transaction, announced from Geneva and Copenhagen on March 2, 2026, is expected to close following Danish foreign direct investment (FDI) approval and customary conditions.
The combined organization aims to accelerate adoption of AI-enabled MSK imaging by integrating complementary technologies, clinical validation, and commercial networks. Both companies will continue operating under their established brands while collaborating closely in research, development, and commercialization.
According to the companies, the merged entity will serve hospitals, imaging centers, and clinics in approximately 90 countries through direct sales and partner channels.
Integrated Portfolio Across X-ray and DXA
The new organization will offer a comprehensive software portfolio covering both acute trauma diagnostics and preventive bone health assessment across X-ray and dual-energy X-ray absorptiometry (DXA).
Key capabilities include:
- Automated fracture detection
- Opportunistic bone fragility assessment
- Fracture risk prediction
- Bone microarchitecture analysis
Medimaps’ solutions — including TBS Osteo™ and TBS Reveal™ — will complement Radiobotics’ RBfracture™ software for trauma-related findings. All tools are designed to integrate into existing radiology workflows via PACS connectivity, supporting routine clinical use without major infrastructure changes.
The companies state that the merger aims to bridge the gap between reactive diagnostics and preventive care by enabling imaging studies to provide both immediate findings and long-term risk insights.
“This merger represents a pivotal milestone in Medimaps Group’s long-term strategy to strengthen our leadership in bone health assessment,” said Univ.-Prof. Dr. Didier Hans, Co-founder and CEO of Medimaps Group. “Our ambition is to give radiologists a single, trusted platform that brings together fracture detection and fracture risk prediction across the continuum of care, so clinicians can make better decisions, patients receive better outcomes, and healthcare systems benefit from more efficient, evidence-based care.”
Addressing Clinical Burden of Fractures and Osteoporosis
Fractures represent a major operational challenge for emergency departments and radiology services due to high patient volumes and the risk of missed diagnoses. Osteoporosis-related fragility fractures alone impose substantial healthcare costs, estimated at $22 billion annually and projected to exceed $95 billion by 2040, according to referenced data.
Early detection of bone fragility and accurate risk assessment are considered essential for preventive treatment strategies. AI-based imaging analysis may help radiologists identify at-risk patients during routine examinations, supporting proactive management.
“Radiobotics has always been driven by scientific rigor and real-world clinical impact,” said Peter Ulvskjold, CEO of Radiobotics and member of the Medimaps Group Executive Committee. “Joining Medimaps Group will accelerate access to our technology. It’s an important step in our vision to ensure patients receive immediate and precise, expert-level care in MSK imaging, 24/7, regardless of time, infrastructure, or staffing constraints.”
Governance and Commercial Strategy
A combined executive team will lead the organization to ensure continuity while preserving the expertise of both companies. The merger is intended to create a collaborative structure capable of scaling distribution and development globally.
Source: Medimaps Group
